Literature DB >> 33974105

A hypothetical future in rheumatology: will we miss steroids in a steroid free-world?

Sakir Ahmed1.   

Abstract

Entities:  

Year:  2021        PMID： 33974105     DOI： 10.1007/s00296-021-04884-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  10 in total

1.  RNA Identification of PRIME Cells Predicting Rheumatoid Arthritis Flares.

Authors:  Dana E Orange; Vicky Yao; Kirsty Sawicka; John Fak; Mayu O Frank; Salina Parveen; Nathalie E Blachere; Caryn Hale; Fan Zhang; Soumya Raychaudhuri; Olga G Troyanskaya; Robert B Darnell
Journal:  N Engl J Med       Date:  2020-07-16       Impact factor: 91.245

2.  Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus.

Authors:  Rita Kansal; Noah Richardson; Indira Neeli; Saleem Khawaja; Damian Chamberlain; Marium Ghani; Qurat-Ul-Ain Ghani; Louisa Balazs; Sarka Beranova-Giorgianni; Francesco Giorgianni; James N Kochenderfer; Tony Marion; Lorraine M Albritton; Marko Radic
Journal:  Sci Transl Med       Date:  2019-03-06       Impact factor: 17.956

3.  Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

Authors:  Marie B Condon; Damien Ashby; Ruth J Pepper; H Terence Cook; Jeremy B Levy; Megan Griffith; Tom D Cairns; Liz Lightstone
Journal:  Ann Rheum Dis       Date:  2013-06-05       Impact factor: 19.103

Review 4.  The complement system as a potential therapeutic target in rheumatic disease.

Authors:  Leendert A Trouw; Matthew C Pickering; Anna M Blom
Journal:  Nat Rev Rheumatol       Date:  2017-08-10       Impact factor: 20.543

5.  Avacopan for the Treatment of ANCA-Associated Vasculitis.

Authors:  David R W Jayne; Peter A Merkel; Thomas J Schall; Pirow Bekker
Journal:  N Engl J Med       Date:  2021-02-18       Impact factor: 91.245

6.  Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.

Authors:  Richard Furie; Brad H Rovin; Frédéric Houssiau; Ana Malvar; Y K Onno Teng; Gabriel Contreras; Zahir Amoura; Xueqing Yu; Chi-Chiu Mok; Mittermayer B Santiago; Amit Saxena; Yulia Green; Beulah Ji; Christi Kleoudis; Susan W Burriss; Carly Barnett; David A Roth
Journal:  N Engl J Med       Date:  2020-09-17       Impact factor: 91.245

7.  High interleukin-18 and low FOXP3 mRNAs in peripheral blood of women with severe systemic lupus erythematosus: a cross-sectional study.

Authors:  Lyuba D Miteva; Irena M Manolova; Mariana G Ivanova; Rumen M Stoilov; Spaska A Stanilova
Journal:  Rheumatol Int       Date:  2020-03-09       Impact factor: 2.631

Review 8.  Targeting interferons and their pathways in systemic lupus erythematosus.

Authors:  François Chasset; Laurent Arnaud
Journal:  Autoimmun Rev       Date:  2017-11-04       Impact factor: 9.754

9.  The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.

Authors:  Tobias Alexander; Ramona Sarfert; Jens Klotsche; Anja A Kühl; Andrea Rubbert-Roth; Hannes-Martin Lorenz; Jürgen Rech; Bimba F Hoyer; Qingyu Cheng; Aderajew Waka; Adriano Taddeo; Michael Wiesener; Georg Schett; Gerd-Rüdiger Burmester; Andreas Radbruch; Falk Hiepe; Reinhard E Voll
Journal:  Ann Rheum Dis       Date:  2015-02-20       Impact factor: 19.103

10.  Rheumatology 4.0: big data, wearables and diagnosis by computer.

Authors:  Gerd R Burmester
Journal:  Ann Rheum Dis       Date:  2018-05-25       Impact factor: 19.103
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.